211 related articles for article (PubMed ID: 24381310)
1. A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.
Kim DW; Park JW; Willingham MC; Cheng SY
Hum Mol Genet; 2014 May; 23(10):2651-64. PubMed ID: 24381310
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α.
Fozzatti L; Kim DW; Park JW; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2013 May; 110(19):7850-5. PubMed ID: 23610395
[TBL] [Abstract][Full Text] [Related]
3. Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha.
Freudenthal B; Shetty S; Butterfield NC; Logan JG; Han CR; Zhu X; Astapova I; Hollenberg AN; Cheng SY; Bassett JHD; Williams GR
Thyroid; 2019 May; 29(5):726-734. PubMed ID: 30760120
[No Abstract] [Full Text] [Related]
4. NCOR1 modulates erythroid disorders caused by mutations of thyroid hormone receptor α1.
Han CR; Park S; Cheng SY
Sci Rep; 2017 Dec; 7(1):18080. PubMed ID: 29273766
[TBL] [Abstract][Full Text] [Related]
5. Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor.
Ying H; Araki O; Furuya F; Kato Y; Cheng SY
Mol Cell Biol; 2007 Mar; 27(6):2359-71. PubMed ID: 17220280
[TBL] [Abstract][Full Text] [Related]
6. NCoR1 regulates thyroid hormone receptor isoform-dependent adipogenesis.
Zhu XG; Kim DW; Goodson ML; Privalsky ML; Cheng SY
J Mol Endocrinol; 2011 Jun; 46(3):233-44. PubMed ID: 21389087
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Hormone Receptor α1 Mutants Impair B Lymphocyte Development in a Mouse Model.
Park S; Zhu X; Kim M; Zhao L; Cheng SY
Thyroid; 2021 Jun; 31(6):994-1002. PubMed ID: 33267733
[No Abstract] [Full Text] [Related]
8. Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors.
Fozzatti L; Lu C; Kim DW; Cheng SY
Mol Endocrinol; 2011 Jun; 25(6):908-21. PubMed ID: 21474540
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Fozzatti L; Park JW; Zhao L; Willingham MC; Cheng SY
PLoS One; 2013; 8(6):e67954. PubMed ID: 23840792
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
[TBL] [Abstract][Full Text] [Related]
12. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1).
Fozzatti L; Lu C; Kim DW; Park JW; Astapova I; Gavrilova O; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17462-7. PubMed ID: 21987803
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
15. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
16. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
18. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone.
Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M
Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262
[TBL] [Abstract][Full Text] [Related]
19. Morphological and Functional Colonic Defects Caused by a Mutated Thyroid Hormone Receptor α.
Kim M; Kruhlak M; Hoffmann V; Zerfas P; Bishop K; Doolittle WKL; Edmondson EF; Zhu YJ; Cheng SY
Thyroid; 2023 Feb; 33(2):239-250. PubMed ID: 36103385
[No Abstract] [Full Text] [Related]
20. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
